lucky slot online game 777
Harry Kane becomes the fastest player to score 50 goals in the BundesligaTim Walz's daughter Hope reveals her 'litmus test' for 'guys who follow Joe Rogan' on Instagram READ MORE: Rogan's explanation for why liberal media is losing audiences View the full results of the US election via our live-updating maps and charts By JAMES GORDON FOR DAILYMAIL.COM Published: 23:40 GMT, 8 December 2024 | Updated: 23:54 GMT, 8 December 2024 e-mail 5 View comments The daughter of Kamala Harris ' running mate Tim Walz has shared her 'litmus test' when it comes to chatting with men online - and it concerns a popular podcast. Hope Walz, 23, who has almost 200,000 followers on TikTok explained how she checks whether potential dates follow Joe Rogan on Instagram - and if they do, it's an instant 'red flag'. 'A litmus test for me and my friends for like years now has been if the guy we're talking to follows Joe Rogan on Instagram , they're a red flag and we should probably stop talking to them,' Walz began. 'And the times when they do follow him on Instagram and we haven't stopped talking to them, it's never ended well,' she explained. Rogan, an MMA color commentator who is highly influential among young men, officially endorsed Donald Trump on the eve of the election - a move Trump’s team touted as a major win in the final hours of their campaign last month. 'I just want to say that I stand by that. It's literally never failed us and at this point it's like the first thing we do when someone starts talking to a new person,' Walz explained in her 90 second video. 'If they follow him we're like, yeah this person probably isn't a great person and probably our values don't align so we're gonna move on from that. And honestly it's worked out well for all of us.' Walz explained that there had 'been some heartbreak' by sticking to the rule but that for the most part it works. The daughter of Kamala Harris' running mate Tim Walz, Hope Walz, 23, has shared her 'litmus test' when it comes to suitable dating partners and it concerns whether they follow Joe Rogan Hope Walz is getting off a campaign plane with her father Governor Tim Walz for a stop on the campaign trial Joe Rogan officially endorsed Donald Trump on the eve of the election, a move Trump’s team touted as a major win in the final hours of their campaign last month 'There's been some heartbreak in there because of it or at least some disappointment but it truly is a litmus test and I got you ladies. You should start doing it,' Walz urged. 'I very much stand by that. He's questionable and unprofessional in my opinion,' she said before directing her message directly at Rogan. 'I don't know how you have the largest podcast in the world and are able to just lie and put out misinformation and straight up lies on your platform,' Walz said. Many of Walz followers praised her for sharing such advice. 'That sinking feeling when they mention something they heard on Joe Rogan’s podcast,' shared one woman in the comments. 'My favorite is when you express your disapproval and then they try and find an episode to show you and it makes it worse,' shared another. 'Asking them how they feel about Taylor Swift also works like a charm (or just mentioning her in general),' added a third. But there were also plenty who didn't agree with with Walz' suggestions. Hope Walz got to know the vice president as her family while campaigned furiously for the Democratic presidential ticket after her father, Minnesota 's governor, was picked as Harris' running mate in August There were also plenty who did not agree with Walz' suggestion 'The whole Walz family are just a bunch of retarded weirdos, aren't they!?' wrote one. 'This child has been brainwashed and successfully indoctrinated. She will never be in touch with reality again,' another stated. Hope Walz got to know the vice president as her family while campaigned furiously for the Democratic presidential ticket after her father, Minnesota 's governor, was picked as Harris' running mate in August. Walz was seen at campaign events with her dad across the country as he met with voters. She also delivered some memorable online social media content of their close relationship from the campaign trail. Joe Rogan Donald Trump TikTok Tim Walz Share or comment on this article: Tim Walz's daughter Hope reveals her 'litmus test' for 'guys who follow Joe Rogan' on Instagram e-mail Add commentTORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug (IND) application. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. Edesa anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S. The study is currently approved in Canada. “This year, Edesa maintained its momentum despite the headwinds in the drug development sector, and we once again validated our TLR4 technology with a third competitive government award,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “I have maintained my strategic support financially and I believe that our team can continue to advance and expand our development pipeline and partnerships.” Edesa's Chief Financial Officer Stephen Lemieux reported that financial results for the fiscal year benefited from prudent use of working capital and effective financial management, including a more than 20% decrease in operating expenses. “Following the end of the fiscal year, we strengthened our balance sheet, and with two governments now funding the advancement of our anti-TLR4 technology, we have improved our position for future financing, potential strategic arrangements as well as other opportunities to advance our pipeline.” Financial Results for the Fiscal Year Ended September 30, 2024 Total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year: Research and development expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company’s completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart. General and administrative expenses decreased by $0.3 million to $4.1 million for year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase salaries and related costs. Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 as a $0.1 million increase in reimbursement funding from the Canadian government's Strategic Innovation Fund was offset by a $0.1 million decrease in interest income. For the year ended September 30, 2024, Edesa reported a net loss of $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023. Working Capital At September 30, 2024, Edesa had cash and cash equivalents of $1.0 million and negative working capital of $0.2 million. Subsequent to the fiscal year end, the company received $1.5 million in gross proceeds under a securities purchase agreement with an entity affiliated with Edesa’s Chief Executive Officer and Founder, and $0.6 million in net proceeds, after deducting sales agent commissions, from common shares sold under an at-the-market offering program. Calendar Edesa management plans to participate in one-on-one meetings during JP Morgan week, which begins on January 13, 2025, in San Francisco, California. Attendees interested in meeting with management can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com . About Edesa Biotech, Inc. Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts . Connect with us on X and LinkedIn . Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: Edesa’s ability to pivot the in-house development of its anti-TLR4 drug candidate; the company’s plans to amend its contribution agreement with the Government of Canada; the company’s goal to maximize synergies between two government-funded projects; Edesa plans to manufacture EB06 and submit related data to the FDA as part of an IND application; the company’s plans to manufacture clinical-grade drug and initiate patient enrollment; the company’s plans to finance clinical and manufacturing activities; the company’s estimate that topline results for its Phase 2 vitiligo study could be available within as few as 12 to 18 months following regulatory clearance; the company’s belief that in 2024 it maintained its momentum despite the headwinds in the drug development sector and once again validated its TLR4 technology with a third competitive government award; the company’s belief that its team can continue to advance and expand its development pipeline and partnerships; the company’s belief that its fiscal year financial results benefited from prudent use of working capital and effective financial management; the company’s belief that with two governments funding the advancement of its anti-TLR4 technology, it has improved its position for future financing, potential strategic arrangements and alternatives as well as other opportunities to advance its pipeline; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Embiid scores 31 in triumphant NBA return for 76ers
Dec 9 (Reuters) - Out-of-form New Zealand opener Devon Conway will miss the third test against England in Hamilton to remain at home for the birth of his first child this week, the team said on Monday. Conway, who scored just 21 runs over four innings as the Black Caps suffered heavy losses in the first two tests, will be replaced in the squad by uncapped all-rounder Mark Chapman. "Family comes first in this environment and we're all really excited for Dev and his wife Kim to welcome their first child," said coach Gary Stead. "Mark was with the test squad in India recently and returned to the Plunket Shield by scoring an impressive 276 - so it's a good time for him to be joining us." The absence of Conway might also give the ultra-loyal Stead the opportunity to bring Will Young into the batting line-up for the final test of the series, which starts at Seddon Park on Saturday. Young scored 244 runs and was named Player of the Series when New Zealand stunned the cricketing world by sweeping India 3-0 in late October and early November but was dropped for Kane Williamson for the England series. Conway's wife Kim went public on social media after suffering a miscarriage at the start of the year, saying she did not want to feel ashamed or embarrassed about it. "We will have our miracle one day and we will love them with everything," she wrote in a post on Instagram. Sign up here. Reporting by Nick Mulvenney, Editing by Toby Davis Our Standards: The Thomson Reuters Trust Principles. , opens new tab
Daily Post Nigeria Nigeria needs listening leaders who don’t act like they know it all – Peter Obi Home News Politics Metro Entertainment Sport News Nigeria needs listening leaders who don’t act like they know it all – Peter Obi Published on November 30, 2024 By Jim Ochetenwu The 2023 Presidential Candidate of the Labour Party, Peter Obi, says Nigeria will do well with leaders who respect popular views about making the country a better place. Obi made the remark in Yola on Saturday as the keynote speaker at the 16th Annual Founder’s Day and 20th Anniversary of the American University of Nigeria, AUN, Yola. He said Nigeria could not hope to develop without leaders who work with the people for national development. “Leaders must be listeners and be ready to learn the right thing and to do it. Leaders must not act as though they know it all,” Obi said. Delivering the Founder’s Day Special Remark during the ceremony, the 2023 presidential candidate of the Peoples Democratic Party, PDP, Atiku Abubakar, defended the establishment of the AUN as a school delivering America-style education. He said he has no apology for developing the university based on the American system, as his wish is for Nigerians and other interested people to be able to receive the sort of education in America without having to go to America. Related Topics: Peter Obi Don't Miss Alleged Coup Plot: I begged Abacha not to execute Obasanjo in 1995 – Gowon You may like Atiku hosts Peter Obi in Adamawa (video) Okonjo-Iweala: Leadership recruitment process must be based on character, competence – Peter Obi Innoson, Benue kidnap: Nigerians no longer sleep with two eyes closed – Peter Obi I’m standing in prayers with you – Peter Obi tells Gov Uno ahead of wife’s burial ‘Nigerians await impact, benefits’ – Peter Obi reacts as Port Harcourt refinery begins operation Nigeria would have been better if Peter Obi won 2023 election – Abaribe Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media LtdEmbiid scores 31 in triumphant NBA return for 76ers
Appeals court rejects emergency bid to ban transgender San Jose State volleyball player from championship tournamentArabians battle past rival MaraudersAssad's rule at stake as Syrian anti-regime forces enter S. Damascus
A protestor wearing a face mask of South Korean President Yoon Suk Yeol in a rally calling for his impeachment in Seoul, South Korea, on Dec 8. SEOUL – Traders are bracing for a period of sustained volatility in South Korean assets as markets reopen on Dec 9, with the won and stocks seen under initial pressure after a weekend of high drama deepened the political crisis. Trading desks are assessing a possibility of a prolonged stalemate after Dec 7’s impeachment motion against President Yoon Suk Yeol failed. With Mr Yoon facing intense pressure to resign, ruling People Power Party leader Han Dong-hoon on Dec 8 said Prime Minister Han Duck-soo will manage the nation’s affairs while his party prepares an orderly exit plan for the President. Opposition lawmakers slammed the decision as unconstitutional and thousands took to the streets to protest. The opposition parties, which together control a majority in parliament, have said they will push quickly for another impeachment vote. The South Korean currency has crept lower in the days following Mr Yoon’s shock declaration of martial law on Dec 3, a decision he reversed within hours after parliament unanimously rejected it. “Had the impeachment motion gone through on Saturday, it would have been over, but Yoon still has control over the military,” said Mr Seo Sang-Young, a market strategist at Mirae Asset Securities. “The ruling party’s boycott will only prolong the domestic uncertainty.” That means volatility will increase, he added, with the market reacting differently by industry. Domestic demand needs an inflow of tourists, and with the tourism balance already negative, this could make things worse, he noted. Chinese tourists visiting South Korea could drop by 19 per cent to 830,000 in the first quarter of 2025 from a year ago on fears of social unrest following the brief imposition of martial law. Such concerns may linger through the Chinese New Year break, according to a Bloomberg Intelligence report. South Korea’s currency, which regained some ground after plunging on Dec 3, briefly dipped again on Dec 6 when a local newspaper reported Mr Yoon may reimpose martial law. It was the worst performing in Asia last week, down almost 2 per cent against the US dollar. “While the martial law declaration has proved short-lived, the won remains weaker than pre-announcement levels and vulnerable to a further drop,” wrote strategists at Barclays. “With the situation remaining highly fluid, the won may remain volatile in the short term.” The Kospi equity benchmark has fallen 2.9 per cent since the short-lived martial law decree, with significant intra-day swings on Dec 6 as traders weighed each political development. “This political instability will have different impacts on different sectors,” said Mr Jung In Yun, chief executive at Fibonacci Asset Management Global, who expects the drama to persist throughout next year. “Exporting companies will likely rebound soon.” “Investors will focus on corporate earnings for the next quarter and assess the impact of the weaker won,” he added. “The Kospi will likely rebound in late December as investors start to segregate political and market issues.” Finance Minister Choi Sang-mok said South Korea will deploy all available measures to deal with the fallout from the political crisis. He said at a media briefing on Dec 8 that the ministry has been cooperating with the Bank of Korea to take pre-emptive measures to respond to volatility in financial and foreign-exchange markets. Intervention could reduce immediate losses for the won, said Mr Sean Callow, senior FX analyst at Intouch Capital Markets in Singapore. “There is likely to be some disappointment over the failed impeachment vote” despite Korean authorities’ efforts to calm investor nerves, he added. “Markets will fear political paralysis so long as Yoon holds on and the PPP protects him from impeachment.” Mr Callow said the underlying trend for the won is still on the downside because of risks linked to the incoming Trump administration’s vow to impose sweeping tariffs. The won was 0.5 per cednt weaker against the dollar at the close on Dec 6, before the failed impeachment attempt. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you. Read 3 articles and stand to win rewards Spin the wheel nowMUNICH (AP) — Harry Kane is the quickest player to score 50 goals in the Bundesliga after scoring a hat trick on his 43rd appearance on Friday. Kane’s three goals – including two penalties – gave Bayern a 3-0 win over Augsburg , stretching the Bavarian powerhouse’s lead to eight points ahead of the rest of the 11th round. Kane scored 36 goals in 32 league appearances last season, his first for Bayern after joining from Tottenham. It was also the first season since 2012 that Bayern failed to win the title, as Bayer Leverkusen went undefeated to snap Bayern's winning run. As well as 14 league goals this season, Kane has scored five in the Champions League and one in the German Cup. Against Augsburg, he had to be patient as Augsburg goalkeeper Nediljko Labrović and his defenders stood firm. “It was somehow typical Harry Kane,” Bayern coach Vincent Kompany said. “It was close in the first half, close, close, close, and then it happens, I think three goals in 15 minutes. Of course, he can do that. But for such a player, I have to say, he had a lot of chances that he could maybe make more of. Then, in an instant, everything is perfect and he can score many goals.” AP soccer: https://apnews.com/hub/soccer
Lisa Simpson once said during an episode of “The Simpsons:” What could be more exciting than the savage ballet that is pro football? On Monday night, the entire Simpsons universe gets to experience it in a way not many could have imagined. The prime-time matchup between the Cincinnati Bengals and Dallas Cowboys will also take place at Springfield’s Atoms Stadium as part of “The Simpsons Funday Football” alternate broadcast. The altcast will be streamed on ESPN+, Disney+, and NFL+ (on mobile devices). ESPN and ABC have the main broadcast, while ESPN2 will carry the final “ManningCast” of the regular season. The replay will be available on Disney+ for 30 days. Globally, more than 145 countries will have access to either live or on replay. “We’re such huge football fans, and the Simpsons audience and the football audience, I feel, are like the same audience of just American families and football. And the Simpsons are so much a part of the DNA of the American family and culture that for us to, like, mush them together in this crazy video game, it’s so fun,” said Matt Selman, executive producer of “The Simpsons.” While the game is the focal point, the alternate broadcast, in some ways, will resemble a three-hour episode of “The Simpsons.” It starts with Homer eating too many hot dogs and having a dream while watching football. Homer joins the Cowboys in the dream while Bart teams up with the Bengals. Lisa and Marge will be sideline reporters. “That’s the beginning of the story, and the story continues through the entire game until Homer wakes up from his dream at the end of the game. It is like a complete story, and the NFL game will happen in between. It’s just going to be an amazing presentation with tons of surprises,” said Michael “Spike” Szykowny, ESPN’s VP of edit and animation. This is the second year ESPN has done an alternate broadcast for an NFL game. It used the characters from “Toy Story” for last year’s Sunday morning game from London between the Atlanta Falcons and Jacksonville Jaguars. “The Simpsons” has featured many sports-themed episodes during its 35 seasons. Even though “Homer at the Bat” remains the consensus favorite sports episode for many Simpsons fans, there have been football ones such as “Bart Star” and “Lisa The Greek.” There also was a Super Bowl-themed one after Fox’s broadcast of Super Bowl 33 between Denver and Atlanta in 1999. Even though “The Simpsons” remains a staple on Fox’s prime-time schedule, it is part of the Disney family after their acquisition of 20th Century Fox in 2019. All 35 seasons are on Disney+. The show’s creators have worked with ESPN and the NFL to make sure the look and sound is definitely Simpsonsesque. The theme song is a mash-up of “The Simpsons” opening and “Monday Night Football’s” iconic “Heavy Action.” There have also been pre-recorded skits and bits to use during the broadcast featuring Simpson’s legendary voices Hank Azaria, Nancy Cartwright, Dan Castellaneta, Julie Kavner, and Yeardley Smith. The telecast will be entirely animated, with the players’ movements in sync with what is happening in real-time on the field. That is done through player-tracking data enabled by the NFL’s Next Gen Stats system and Sony’s Beyond Sports Technology. While Next Gen Stats tracks where players are on the field with a tracking chip in the shoulder pads, there is skeletal data tracking and limb tracking data — which uses 29 points per player — to get closer to the player’s movements. The other data tracking will allow Beyond Sports and Disney to add special characters to the game. For example, there might be a play where Lisa catches the ball and goes 30 yards instead of Cincinnati’s Tee Higgins. “Lisa is much smaller than the rest of the players. So, in real life, the ball would go over her head, but now, with data processing, we can take the ball and make it go exactly into her hands. So for the viewer, it still looks believable, and it all makes sense,” said Beyond Sports co-founder Nicolaas Westerhof. The other major challenge is making “The Simpsons” two-dimensional cartoon characters into 3-D simulations. Szykowny and his team worked to make that a reality over the past couple of months. “That’s a big leap of faith for them to say, hey, we trust you to make our characters 3-D and work with it. Our ESPN creative studio team has done a wonderful job,” Szykowny said. Lisa, Krusty, Nelson, Milhouse and Ralph will be with Bart and the Bengals; while Carl, Barney, Lenny and Moe join up with with Homer and the Cowboys. The broadcast will also feature ESPN personalities Stephen A. Smith, Peyton Manning and Eli Manning. ESPN’s Drew Carter, Mina Kimes and Dan Orlovsky will call the game from Bristol, Connecticut, and also be animated. They will wear Meta Quest Pro headsets to experience the game from Springfield using VR technology. For Kimes, being part of the broadcast and being an animated Simpsons character is a dream come true. She is a massive fan of the show and has a framed photo of Lisa Simpson — who she said is a personal hero and icon — as part of her backdrop when she makes appearances on ESPN NFL shows from her home in Los Angeles. “I didn’t have any input, and I didn’t see anything beforehand, so I wasn’t sure if it would look like me, but it kind of does, which is very funny,” said Kimes, who drew Simpsons characters when she was a kid. “To see the actual staff turn me into one was a dream.” Even though the Bengals (4-8) and Cowboys (5-7) have struggled this season, Selman thinks both teams have personalities that appeal to “The Simpsons” universe. “We were just so lucky also that the Cowboys are sort of like a Homer Simpson-type team, American team, and Mike McCarthy might be a Homer-type guy, one might imagine,” he said. ”And then you have Joe Burrow on the other side who is a cool young, spiky-haired, blonde bad boy -- he’s like Bart. And that fits our character archetypes so perfectly. “If Homer is mad at Bart and has a hot dog dream while watching ’Monday Night Football’, and then it’s basically McCarthy versus Burrow, Homer versus Bart, and that’s the simple father versus son strangling — Homer strangling Bart dynamic that has been part of the show for 35 years. I don’t know if that would have worked as well if it was like Titans versus Jacksonville. We would have found something. We would have made it work.” ___ AP NFL: https://apnews.com/hub/nflFormer choreographer Sonya Tayeh paid tribute to her late costar ahead of the second anniversary of his death. At the opening night celebration of on Oct. 25, Tayeh — who serves as the Broadway production’s movement director and choreographer — opened up to PEOPLE about the lasting impact of tWitch, who died by in December 2022. “It's not every day where you meet someone that is already so transcendent,” Tayeh, 47, shared. “He is an angel in our lives.” Related: FOX via Getty tWitch competed on in 2008, ending season 4 as a runner-up and later returning as an All-Star. He was when the show returned in 2022. She added that the late dancer and choreographer “moved my world when I would watch him dance and took my breath away and we had the most invigorating in-depth conversations about family and art and the world, and he changed my way of thinking about movements and made an imprint on my heart that I will never be able to articulate.” “Even standing here now, he is someone that is beyond, he is someone that has spread so much love and wholeness to our lives and I will never forget,” she added. Related: Following the news of tWitch’s death, Tayeh joined a chorus of his former costars in remembering the television personality. Cindy Ord/Getty In a statement to PEOPLE at the time, she shared: "Blessed beyond belief to be in the presence of Twitch (I called him Twizzle). The gift he gave to our beloved dance community is boundless.” "Watching him dance was like watching a marvel of the craft grace us," she added. "He will be forever in our cells." Related: also remembered her late husband on the second anniversary on Dec. 13. She of the pair posing alongside their children on social media and wrote, "Our Angel is watching over us and protecting us." "You are always on our hearts and we will always love you," she added. "We miss you Stephen. 2 years with you not here but you are always on our minds. We love you." Read the original article on
What happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-Cowboys
N.J. scratch-off lottery player cures ‘bad day’ with $1M win
Israel and Lebanon's Hezbollah start a ceasefire after nearly 14 months of fightingKash Patel: The die-hard loyalist
The best Black Friday TV deals still availableNewport throw away lead to draw, Yachtsmen crushed and Vics lose top of table clash
Sonya Tayeh Says Former “SYTYCD” Costar tWitch 'Took My Breath Away' When Dancing: 'Changed My Way of Thinking' (Exclusive)Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen
The Chairman of the Independent National Electoral Commission, Prof. Mahmood Yakubu, on Sunday commended Ghana’s electoral process, highlighting its innovations and political stability as key factors in the smooth conduct of the elections. Ghana’s former President John Mahama won the country’s presidential election held on Saturday, December 7, 2024, after his main opponent, Vice President Mahamudu Bawumia, conceded defeat. According to AFP, the Election Commission had said the official results were likely to be announced by Tuesday. The INEC chairman, who monitored the election and spoke in a short video obtained by our correspondent, observed the political stability inherent in Ghana’s democracy, noting the consistency of its political party structures and voter loyalty. Yakubu cited the perseverance of the main opposition candidate, a former vice president and president, who contested multiple elections before achieving success. “Rarely in Ghana do you see people moving from one party to another with every general election. So, that is important. “It provides stability.It also provides their supporters stability. So, there are people who support political parties for many years. So, whether the party is in power or in opposition, they stick to the political party,” he added. The INEC Chairman also noted that Ghana’s approach to managing results at the constituency level, inspired by Nigeria, has improved the efficiency of the electoral process. Previously, all parliamentary and presidential results were sent to the Electoral Commission headquarters in Accra for announcement. However, Ghana has adopted a decentralised system, allowing constituency-level officers to announce parliamentary results locally, while only presidential results are sent to Accra. Related News Ghana: CJID, DUBAWA harp on credible polls Jonathan leads West Africa Elders Forum to Ghana election Ghana’s deputy finance minister pulls gun on youths in self-defence “The second thing for me is the lesson that Ghana also learnt from Nigeria in the area of managing constituency election results. Until the last election in Ghana, all results come to the Electoral Commission headquarters in Accra; that is parliamentary and presidential. “Although Ghana is not a federal system, they learnt from Nigeria where you have returning officers that announce results for parliamentary elections in the various constituencies around the country. Only the presidential election results come to Accra. “In Nigeria, this is what we have done and they borrowed a leave from us and this is the second time they are implementing that. That is why, as you can see, the declaration of the presidential election result was a lot faster than it used to be in the past,” he explained. Expressing satisfaction with the process, Yakubu stated, “We are grateful that the election has gone very well. The process and its outcome so far have been commendable, and we continue to support our colleagues in Ghana’s Electoral Commission.” The defeat in Saturday’s election ends two terms in power for the governing New Patriotic Party under President Nana Akufo-Addo, marked by Ghana’s worst economic crisis in years, involving high inflation and a debt default. Mahama, who was president of Ghana between July 2012 and January 2017, confirmed on X he had received Bawumia’s congratulatory call over his “emphatic victory.” AFP reported that with a history of democratic stability, Ghana’s two main parties, the NPP and NDC, have alternated in power since the return to multi-party politics in 1992. Under the slogan “Break the 8” — a reference to two terms in power — Bawumia had sought to lead the NPP to an unprecedented third term. However, he struggled to overcome criticism of Akufo-Addo’s economic record. Although inflation slowed from more than 50 per cent to around 23 per cent and other macroeconomic indicators stabilised, economic struggles remained a key issue for many voters. This frustration paved the way for Mahama’s comeback challenge. Mahama, who served as president from 2012 to 2017, had previously failed in two presidential bids.